• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure.晚期肝细胞癌的局部区域与全身联合治疗：最终，前景仍不明朗。
Ann Transl Med. 2020 Dec;8(24):1700. doi: 10.21037/atm-20-4164.
2
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
3
Battle Royale: Systemic Versus Locoregional Therapy for Unresectable Hepatocellular Carcinoma.《大逃杀：不可切除肝细胞癌的系统治疗与局部区域治疗》。
AJR Am J Roentgenol. 2018 Jun;210(6):1366-1367. doi: 10.2214/AJR.17.19392. Epub 2018 Apr 18.
4
Pre- and post- operative adjuvant targeting locoregional chemotherapy combined with locoregional targeting immunostimulation and surgical resection for hepatocellular carcinoma. A new promising alternative.术前和术后辅助性局部区域靶向化疗联合局部区域靶向免疫刺激及手术切除治疗肝细胞癌。一种新的有前景的替代方案。
Anticancer Res. 1994 May-Jun;14(3B):1351-5.
5
Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.全身治疗在肝细胞癌中的作用及未来方向
Cancer Control. 2017 Jul-Sep;24(3):1073274817729243. doi: 10.1177/1073274817729243.
6
Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.经动脉联合靶向局部免疫治疗-化疗用于不可切除肝细胞癌患者：解决老问题的新选择
J Interferon Cytokine Res. 1995 May;15(5):467-72. doi: 10.1089/jir.1995.15.467.
7
Systemic treatment of advanced hepatocellular cancer: new hope on the horizon.晚期肝细胞癌的系统治疗：新希望在望。
Expert Rev Anticancer Ther. 2019 Apr;19(4):343-353. doi: 10.1080/14737140.2019.1585245. Epub 2019 Mar 11.
8
Treatment of hepatocellular carcinoma: present and future.肝细胞癌的治疗：现状与未来。
Expert Rev Anticancer Ther. 2013 Apr;13(4):469-79. doi: 10.1586/era.13.21.
9
Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy.肝癌局部和系统治疗反应的影像学评估。
AJR Am J Roentgenol. 2013 Jul;201(1):80-96. doi: 10.2214/AJR.13.10706.
10
A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials.一种针对无法接受局部区域治疗的晚期肝细胞癌患者的新预后评分系统：对全身治疗试验患者选择的意义。
Cancer. 2008 Nov 15;113(10):2742-51. doi: 10.1002/cncr.23878.

引用本文的文献

1
Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study.探索患者偏好在肝细胞癌治疗决策中的作用：一项定性研究。
MDM Policy Pract. 2025 May 29;10(1):23814683251340055. doi: 10.1177/23814683251340055. eCollection 2025 Jan-Jun.
2
A Comparative Study of Antitumor Immunity Induced by Radiofrequency Microwave and Cryoablation in Hepatocellular Carcinoma.射频微波与冷冻消融治疗肝癌的抗肿瘤免疫比较研究。
Appl Biochem Biotechnol. 2024 Jul;196(7):4088-4104. doi: 10.1007/s12010-023-04760-y. Epub 2023 Oct 27.
3
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.肝细胞癌的系统治疗：基于中国共识的多学科专家声明
Liver Cancer. 2022 Jan 4;11(3):192-208. doi: 10.1159/000521596. eCollection 2022 Jun.
4
Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies.肝细胞癌的经皮治疗：肝脏定向治疗的演变
J Hepatocell Carcinoma. 2021 Sep 23;8:1181-1193. doi: 10.2147/JHC.S268300. eCollection 2021.

本文引用的文献

1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
2
Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?钇-90 放射性栓塞治疗巴塞罗那临床肝癌分期 C 期患者：Child-Pugh A 级与 B 级患者的结果是否相当？
Cardiovasc Intervent Radiol. 2020 May;43(5):721-731. doi: 10.1007/s00270-020-02434-4. Epub 2020 Mar 5.
3
Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial.肝定向同步放化疗序贯索拉非尼治疗晚期肝细胞癌的疗效和安全性：一项前瞻性 2 期试验。
Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):106-115. doi: 10.1016/j.ijrobp.2020.01.027. Epub 2020 Feb 19.
4
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
5
Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.肝细胞癌的免疫肿瘤学疗法：现状与正在进行的试验
Liver Cancer. 2019 Jul;8(4):221-238. doi: 10.1159/000501501. Epub 2019 Jul 9.
6
A global view of hepatocellular carcinoma: trends, risk, prevention and management.全球视角下的肝细胞癌：趋势、风险、预防与管理。
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22.
7
Insights into the success and failure of systemic therapy for hepatocellular carcinoma.对肝细胞癌系统治疗成败的深入了解。
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):617-630. doi: 10.1038/s41575-019-0179-x. Epub 2019 Aug 1.
8
Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.优化肝癌的免疫检查点阻断放疗。
World J Gastroenterol. 2019 May 28;25(20):2416-2429. doi: 10.3748/wjg.v25.i20.2416.
9
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.瑞戈非尼治疗后索拉非尼治疗失败的晚期肝细胞癌患者的 Ramucirumab（REACH-2）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.
10
Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis.基于立体定向体部放疗治疗广泛门静脉癌栓的肝细胞癌。
Radiat Oncol. 2018 Sep 25;13(1):188. doi: 10.1186/s13014-018-1136-5.

Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure.

作者信息

Farsad Khashayar, Nabavizadeh Nima, Kardosh Adel, Jou Janice H, Naugler Willscott E, Kolbeck Kenneth J

机构信息

Department of Interventional Radiology, Dotter Interventional Institute, Oregon Health and Science University, Portland, OR, USA.

Department of Radiation Oncology, Oregon Health and Science University, Portland, OR, USA.

出版信息

Ann Transl Med. 2020 Dec;8(24):1700. doi: 10.21037/atm-20-4164.

DOI:10.21037/atm-20-4164
PMID:33490212
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7812172/
Abstract
摘要